Virtu Financial LLC Trims Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Virtu Financial LLC trimmed its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 32.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,647 shares of the company’s stock after selling 24,479 shares during the quarter. Virtu Financial LLC’s holdings in Atossa Therapeutics were worth $77,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Intech Investment Management LLC bought a new stake in Atossa Therapeutics during the 3rd quarter worth approximately $29,000. XTX Topco Ltd purchased a new position in shares of Atossa Therapeutics during the 2nd quarter valued at $29,000. SG Americas Securities LLC increased its holdings in shares of Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Atossa Therapeutics in the third quarter worth $75,000. Finally, Rhumbline Advisers bought a new stake in Atossa Therapeutics during the second quarter valued at $161,000. 12.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th.

Atossa Therapeutics Stock Down 1.0 %

Shares of ATOS stock opened at $0.98 on Friday. The firm has a market cap of $123.28 million, a P/E ratio of -4.45 and a beta of 1.21. The business has a 50-day moving average price of $1.32 and a two-hundred day moving average price of $1.32. Atossa Therapeutics, Inc. has a 12-month low of $0.71 and a 12-month high of $2.31.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.